MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games

Chemotherapy-free

Search medical newsFind research, conditions and clinical updates
  • Home
  • Chemotherapy-free
Ponatinib 联合 Blinatumomab 对比 Imatinib 联合化疗:推进成人 Philadelphia 染色体阳性 ALL 的一线治疗
Posted inHematology-Oncology news Oncology

Ponatinib Plus Blinatumomab vs. Imatinib And Chemotherapy: Advancing Frontline Therapy in Adult Philadelphia-Positive ALL

Posted by By MedXY 10/21/2026
This phase 3 trial demonstrates that a chemotherapy-free regimen combining ponatinib and blinatumomab significantly improves event-free survival over imatinib plus chemotherapy in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Read More
Chemotherapy-Free Frontline Therapy in Indolent B-Cell Non-Hodgkin Lymphoma: Insights from Mosunetuzumab and Response-Adapted Polatuzumab Vedotin with Obinutuzumab
Posted inHematology-Oncology news Oncology

Chemotherapy-Free Frontline Therapy in Indolent B-Cell Non-Hodgkin Lymphoma: Insights from Mosunetuzumab and Response-Adapted Polatuzumab Vedotin with Obinutuzumab

Posted by By MedXY 08/17/2026
A novel chemotherapy-free regimen combining mosunetuzumab with response-adapted polatuzumab vedotin and obinutuzumab shows high complete response rates and durable progression-free survival in untreated indolent B-cell NHL with favorable safety.
Read More

Take a game break

Explore a few games from MedXY.

Explore all games
  • Targeting ANGPTL4 with MAR001: A Promising Approach for Reducing Elevated Triglycerides
  • Enhancing Muscle Endurance: The Impact of Superimposed Tendon Vibration on Isometric Knee Extension Fatigue
  • Enhancing Reactive Balance in Incomplete Spinal Cord Injury: Evaluating the Impact of Functional Electrical Stimulation Combined with Reactive Balance Training
  • Assessing Risks and Safety in Pediatric Dental Sedation: Insights from Claims Data Analysis (2014-2019)
  • Pathotype-Specific Gene Expression Illuminates Genetic Susceptibility in Early Rheumatoid Arthritis
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk case report chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation machine learning MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top